Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice

Japanese Journal of Cancer Research

Volumn 91, Issue 6, 2000, Pages 622-628

  Sato, Noriko ^a   Saga, Tsuneo ^a   Sakahara, Harumi ^a,d   Nakamoto, Yuji ^a   Zhao, Songji ^a,e   Kuroki, Masahide ^b   Iida, Yasuhiko ^a   Endo, Keigo ^c   Konishi, Junji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antibody; Avidin chase; Liver metastasis; Myelotoxicity; Radioimmunotherapy

Indexed keywords

AVIDIN; BIOTIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; BLOOD CELL COUNT; BONE MARROW; BONE MARROW TOXICITY; COLON CANCER; CONTROLLED STUDY; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN CELL; IRRADIATION; LEUKOPENIA; LIVER METASTASIS; MAXIMUM PERMISSIBLE DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; WEIGHT REDUCTION;

EID: 0033947837     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00991.x     Document Type: Article

References (30)

1. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Schlom, J., Russell, C. D., Liu, T. and LoBuglio, A. F. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Medl., 35, 1017-1022 (1994).
2. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Vagg, R. C., Ying, Z., Zhang, C.-H., Swayne, L. C., Vardi, Y., Siegel, J. A. and Goldenberg, D. M. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. Nucl. Med., 38, 858-870 (1997).
3. Behr, T. M., Goldenberg, D. M. and Becker, W. S. Radioimmunotherapy of solid tumors: a review "of mice and men." Hybridoma, 16, 101-107 (1997).
4. Vogel, C. A., Galmiche, M. C. and Buchegger, F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res., 57, 447-453 (1997).
5. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Ying, Z., Zhang, C.-H., Siegel, J. A. and Goldenberg, D. M. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J. Nucl. Med., 38, 409-418 (1997).
6. Hagan, P. L., Halpern, S. E., Dillman, R. O., Shawler, D. L., Johnson, D. E., Chen, A., Krishnan, L., Frincke, J., Bartholomew, R. M., David, G. S. and Carlo, D. Tumor size: effect on monoclonal antibody uptake in tumor models. J. Nucl. Med., 27, 422-427 (1986).
7. Fowler, J. F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys., 18, 1261-1269 (1990).
8. Saga, T., Sakahara, H., Nakamoto, Y., Sato, N., Zhao, S., Iida, Y., Kuroki, M., Endo, K. and Konishi, J. Radioimmunotherapy for liver micrometastases in mice: pharmacokinetics, dose estimation, and long-term effect. Jpn. J. Cancer Res., 90, 342-348 (1999).
9. Sato, N., Saga, T., Sakahara, H., Nakamoto, Y., Zhao, S., Iida, Y., Kuroki, M., Matsuoka, Y. and Konishi, J. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. J. Nucl. Med., 40, 685-692 (1999).
10. Muthuswamy, M. S., Robersin, P. L. and Buchsbaum, D. J. A mouse bone marrow dosimetry model. J. Nucl. Med., 39, 1243-1247 (1998).
11. 131I-labeled anti-body to carcinoembryonic antigen in cancer radioimmunotherapy. J. Natl. Cancer Inst., 81, 194-199 (1989).
12. Sharkey, R. M., Primus, F. J. and Goldenberg, D. M. Second antibody clearance of radiolabeled antibody in cancer radioimmunodetection. Proc. Natl. Acad. Sci. USA, 81, 2843-2846 (1984).
13. Casey, J. L., King, D. J., Pedley, R. B., Boden, J. A., Boden, R., Chaplin, L. C., Dorning, M. and Begent, R. H. J. Clearance of yttrium-90-labeled anti-tumor antibodies with antibodies raised against the 12N4 DOTA macrocycle. Br. J. Cancer, 78, 1307-1312 (1996).
14. Klibanov, A. L., Martynov, A. V., Slinkin, I. Y., Smirnov, M. D., Muzykantov, V. R., Danilov, S. M. and Torchilin, V. P. Blood clearance of radiolabeled antibody: enhancement by lactosamination and treatment with biotin-avidin or antimouse IgG antibodies. J. Nucl. Med., 29, 1951-1956 (1988).
15. Kobayashi, H., Sakahara, H., Hosono, M., Yao, Z., Toyama, S., Endo, K. and Konishi, J. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. J. Nucl. Med., 35, 1677-1684 (1994).
16. 2 fragments of an anti-tumor antibody. Br. J. Cancer, 71, 18-24 (1995).
17. Chen, J. Q., Atrand, S.-E., Tennvall, J., Lindgren, L., Hidorf, C. and Sjögren, H.-O. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96. J. Nucl. Med., 38, 1934-1939 (1997).
18. Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A. and Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in mouse model of experimental liver metastasis. J. Clin. Invest., 95, 1789-1797 (1995).
19. Kuroki, M., Arakawa, F., Higuchi, H., Matsunaga, A., Okamoto, N., Takakura, K. and Matsuoka, Y. Epitope mapping of the carcinoembryonic antigen by monoclonal antibodies and establishment of a new improved radioimmunoassay system. Jpn. J. Cancer Res. (Gann), 78, 386-396 (1987).
20. Green, N. M. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem. J., 94, 23c-24c (1965).
21. Hunter, W. N. and Greenwood, F. C. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature, 194, 495-496 (1962).
22. Lindmo, T., Boven, E., Cuttitta, F., Fedorco, J. and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72, 77-89 (1984).
23. Bardies, M. and Chatal, J.-F. Absorbed dose for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. Phys. Med. Biol., 39, 961-981 (1993).
24. Press, O. W., Farr, A. G., Borroz, K. I., Anderson, S. K. and Martin, P. J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res., 49, 4906-4012 (1989).
25. Kobayashi, H., Sakahara, H., Endo, K., Yao, Z., Toyama, S. and Konishi, J. Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity. Eur. J. Cancer, 31, 1689-1696 (1995).
26. Vriesendorp, H. M., Quadri, S. M., Andersson, B. S. and Dicke, K. A. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp. Hematol., 24, 1183-1190 (1996).
27. Neta, R., Douches, S. and Oppenheim, J. J. Interleukin 1 is a radioprotector. J. Immunol., 136, 2483-2485 (1986).
28. Blummenthal, R. D., Sharkey, R. M. and Goldenberg, D. M. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression. J. Natl. Cancer Inst., 84, 399-407 (1992).
29. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res., 55 (Suppl.), 5916s-5920s (1995).
30. Schlom, J., Molinolo, A., Simpson, J. F., Siler, K., Roselli, M., Hinkle, G., Houchens, D. P. and Colcher, D. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J. Natl. Cancer Inst., 82, 763-771 (1990).